Skip to main content
. 2019 Dec 30;111(2):312–322. doi: 10.1111/cas.14274

Table 2.

Off–target gene mutations identified in patients during treatments with gilteritinib and crenolanib

  Gilteritinib Crenolanib
RAS/MAPK pathway genes

NRAS, KRAS, PTPN11

CBL, BRAF

NRAS, KRAS, PTPN11
Epigenetic‐modifying genes IDH2

IDH1, IDH2

TET2, DNMT3A

ASXL1, BCOR

Myeloid transcription factor genes

CEBPA

RUNX1

CEBPA

RUNX1

Spliceosome‐complex genes  

U2AF1

SF3B1

Cohesion complex genes   STAG2
Others

WT1

TBL1XR1

BCR‐ABL